麻豆传媒

Nivolumab/ipilimumab led to improvement in untreated MSI-H/dMMR disease versus chemo

But will the benefit extend to event-free and overall survival?

Adding durvalumab and bevacizumab to transarterial chemoembolization almost doubles PFS

Lutetium dotatate reduces PFS risk by 72% in randomized trial

But how much did investigational tiragolumab contribute to efficacy?

Three times as many patients alive at 5 years with chemo plus pembrolizumab

Significant improvement in OS, PFS with addition of bevacizumab to trifluridine/tipiracil

No survival benefit with three-drug chemo regimen or clear PFS gain with anti-PD-L1/bevacizumab

Liposomal irinotecan regimen boosts outcomes, although expert expressed concern about toxicity

Longest overall survival reported to date with the addition of zolbetuximab to chemotherapy

Nearly identical 3-year survival, questioning the need for radiotherapy before surgery

Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer

The KRAS G12C inhibitor showed a disease control rate of 100% in small study

Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade